【摘要】 目的:评估齐拉西酮合并氯硝西泮治疗精神分裂症患者急性期兴奋激越的有效性和安全性。方法:120例中度急性期伴激越患者,随机分为齐拉西酮合并氯硝西泮治疗组和奥氮平治疗组,分别在治疗基线、第4天、第7天、第14天和第28天进行疗效和安全性评估。共脱落22例,98例纳入分析。结果:①阳性与阴性症状量表(PANSS)的减分值在两组药物之间差异无统计学意义(F=0.264,P=0.608);兴奋条目总分的时间变化趋势差异有统计学意义(F=194.984,P=0.000),而在两组药物之间差异无统计学意义(F=0.047,P=0.828);②两组间体质量、三酰甘油和胆固醇差值比较差异有统计学意义(F=4.274,P=0.041;F=4.967,P=0.028;F=3.991,P=0.049),奥氮平组体质量、血脂变化高于齐拉西酮组;③两组不良反应量表(UKU)比较,时间趋势有统计学差异(F=4.9,P=0.002),分组因素无统计学差异(F=1.425,P=0.236)。结论:齐拉西酮合并氯硝西泮治疗急性期伴有兴奋激越的精神分裂症患者的疗效与奥氮平相当,但对体质量和血脂的影响小于奥氮平。更多还原

【Abstract】 Objective:To investigate the efficacy and adverse profiles of ziprasidone combined with clonazepam for treatment of acute agitation in schizophrenia.Method:A total of 120 schizophrenic patients with moderate acute agitation was randomized to receive ziprasidone combined with clonazepam or olanzapine treatment.Clinical effects were monitored by the positive and negative syndrome scale(PANSS) and side effects by the UKU(Udvalg for Kliniske Undersogelser side effect rating scale) at the baseline,4 days,7 days,14 days and 28 days.22 cases were off and 98 cases were analyzed.Results:①The reduced scores of PANSS between the two groups were no significant difference(F=0.264,P=0.608);The scores of the PANSS excited componets(PANSS-EC) were significant difference(F=194.984,P=0.000) in observed points,while no significant difference between the two groups(F=0.047,P=0.828);②The level of weight,triglycerides and cholesterol were significant difference in two groups(F=4.274,P=0.041;F=4.967,P=0.028;F=3.991,P=0.049).The changes of weight,triglycerides and cholesterol in olanzapine group were more higher than in ziprasidone;③Compare to the scores of UKU,time factors were significantly different(F=4.9,P=0.002) and group factors were no statistically significant difference(F=1.425,P=0.236).Conclusion:Ziprasidone combined with clonazepam and olanzapine demonstrate similar efficacy for acute agitation in schizophrenia.The change of weight and lipemia in group of olanzapine are more than in ziprasidone.更多还原